



**COMPANY ANNOUNCEMENT
16 AUGUST 2005**

**NEUROSOLUTIONS TO ATTEND AND PRESENT WITH
GLAXO SMITHKLINE AT 11TH WORLD CONGRESS ON PAIN
IN SYDNEY**

NeuroDiscovery Ltd (**NeuroDiscovery** or **Company**) (ASX Code:NDL), a neurology-focused biotechnology company, is pleased to announce its 100% subsidiary, NeuroSolutions Ltd (**NeuroSolutions**) will be attending and presenting a joint research paper with one its largest clients, Glaxo SmithKline, at the 11th World Congress on Pain in Sydney from August 21st to 26th 2005.

The international multidisciplinary Congress is intended to provide delegates with an overview of the state-of-the-art range of topics in the areas of acute and chronic pain; to provide practical reviews of current research and therapies in these areas; and to enable delegates to participate in formal and informal discussions with international experts.

NeuroSolutions attendance at the Congress is important for promoting the company's profitable neurology services and neuropathic pain research and development pipeline, in particular the company's lead compound which is expected to enter a clinical trial this year.

NeuroSolutions' Chief Executive Officer, Dr Alistair Dixon said "The World Congress on Pain provides the company with a unique opportunity to pursue collaborations and services offerings with both Australasian and other International organisations and in addition reinforce the approach we are taking in an attempt to bring new pain remedies to the market place."

-ENDS-

For further information please contact:

*David McAuliffe
Executive
NeuroDiscovery
Mobile: 0408 994 313
macdavid@inet.net.au*

*Claire Stannard
Clarity Communications
PH: 9380 0700
MB: 0409 189 410
claire@claritycommunications.com.au*

Background Information

About NeuroDiscovery

NeuroDiscovery Ltd is an ASX listed neurology research and development company which owns 100% of NeuroSolutions Ltd (ASX Code NDJ).

About NeuroSolutions

NeuroSolutions Limited is a profitable service company, applying its broad expertise and drug discovery platforms to become a leading provider of specialised electrophysiological assays to the biopharmaceutical industry. Electrophysiology is a specialised technique which is used to record electrical activity in membranes, cells, tissues or in vivo. NeuroSolutions current clients include many other established pharmaceutical and biotechnology companies. In parallel to running its service business, the Company is also exploiting its in house technologies and expertise for its own internal R&D and has a mature pipeline of programmes underway for the treatment of pain.

About Neuropathic Pain

Neuropathic pain is defined by the International Association for the Study of Pain (IASP) as 'any pain syndrome in which the predominating mechanism is a site of aberrant somatosensory processing in the peripheral or central nervous system. Some clinical neuroscientists restrict this definition to pain originating in peripheral nerves and nerve roots.'

Despite continuing intensive research, the treatment of these disorders remains surprisingly poor. Current therapies for neuropathic pain and post-operative hyperalgesia are based on "off label" use of gabapentin, CNS depressants or largely ineffective long-term opioids and non-steroidal anti-inflammatory drugs (NSAIDs). New participants in the neuropathic pain market have been greatly encouraged by this unmet medical need among end- users, as it provides them with the perfect opportunity to move into this space. It is forecasted that revenues in the sector will rise from \$2.48 billion in 2003 to \$4.83 billion by 2010 (Frost & Sullivan, 2004).